ClouDr Group Limited

Equities

9955

KYG2216H1011

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:05 2024-07-18 EDT 5-day change 1st Jan Change
1.82 HKD +1.11% Intraday chart for ClouDr Group Limited +3.41% -73.43%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
ClouDr Group to Sell Blood Circulation Drug in China MT
ClouDr Group Limited Announces Resignation of Director and Change in Composition of Audit Committee CI
China Accepts Marketing Application for ClouDr Unit's Vitamin B6 Injection MT
ClouDr Group Limited Announces Application for Market Launch of Vitamin B6 Injection Solution CI
ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services MT
ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5% MT
ClouDr Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ClouDr Launches Diabetes Tablets; Shares Up 3% MT
ClouDr Group Limited Announces Launch of Proprietary Product, Hetangjin Dapagliflozin Tablets CI
ClouDr Group Limited Enters into A Non-Legally Binding Strategic Cooperation Agreement with China Resources Kunming Shenghuo Pharmaceutical Co., Ltd CI
ClouDr Buys Back Shares MT
ClouDr Group Trustee Buys 1.3 Million Shares Under Award Scheme MT
ClouDr Unit to Get 200 Million Yuan Capital Injection MT
ClouDr Buys Back Shares for Incentive Scheme MT
ClouDr Group Applies to Register Diabetes Digital Therapeutics in China MT
ClouDr Group Limited Completes the Application for Registration as A Medical Device in the People's Republic of China in Respect of ClouDT-01 CI
ClouDr Group to Buy Up to HK$80 Million of Shares MT
ClouDr Signs Marketing Deal With Shanxi Jinbo Bio Pharmaceutical MT
ClouDr Group Limited Enters into a Non-Legally Binding Strategic Cooperation Agreement with Shanxi Jinbo Bio-Pharmaceutical Co., Ltd CI
Cloudr Group Limited Announces Resignation of Liu Mengya as Joint Company Secretary CI
ClouDr Group Signs Digital Marketing Agreement with Pharmaceutical Company MT
ClouDr Says New Evidence Shows Ischelium Drug's Efficacy on Cognitive Improvement MT
ClouDr Group Limited Announces New Efficacy of Ischelium on Brain Covidative Fund Approval CI
ClouDr to be Added in MSCI China Small Cap Index MT
ClouDr Group Chairman/CEO Boosts Shareholding MT
Chart ClouDr Group Limited
More charts
ClouDr Group Ltd is a China-based holding company principally engaged in the provision of medical services and products. The Company provides medical supplies and software-as-a-service (SaaS) products to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultations and prescriptions to patients. The Company's product portfolio consists of three major product or service categories. The in-hospital solution mainly includes hospital supplies sales, hospital SaaS and digital marketing services. The pharmacy solution mainly includes pharmacy supplies sales and pharmacy SaaS. The individual chronic condition management solution and others mainly include chronic condition products, premium membership services, as well as insurance brokerage services, advertisement agent services and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.692 CNY
Average target price
3.086 CNY
Spread / Average Target
+82.40%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 9955 Stock
  4. News ClouDr Group Limited
  5. ClouDr Group to Sell Blood Circulation Drug in China